K Pharma,Inc. (4896.T)
JPY 632.0
(-1.25%)
JPY 632.0
(-1.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 260.33 Million JPY | 166.34% |
| 2022 | -392.42 Million JPY | -71.58% |
| 2021 | -228.71 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -193.05 Million JPY | 17.3% |
| 2024 Q1 | -233.44 Million JPY | -69.31% |
| 2023 Q3 | -116.55 Million JPY | 0.0% |
| 2023 Q4 | -137.88 Million JPY | -18.29% |
| 2023 FY | 260.33 Million JPY | 166.34% |
| 2022 FY | -392.42 Million JPY | -71.58% |
| 2021 FY | -228.71 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 32.206% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 149.407% |
| GNI Group Ltd. | 8.09 Billion JPY | 96.784% |
| Linical Co., Ltd. | 338.26 Million JPY | 23.04% |
| Trans Genic Inc. | 4.08 Million JPY | -6272.827% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 118.104% |
| Soiken Holdings Inc. | -662.2 Million JPY | 139.313% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -88.433% |
| AnGes, Inc. | -7.43 Billion JPY | 103.5% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 120.21% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 103.619% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -39.442% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 133.376% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 122.581% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 121.533% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 132.044% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 180.433% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 121.338% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 118.306% |
| PeptiDream Inc. | 3.03 Billion JPY | 91.425% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 113.429% |
| Ribomic Inc. | -1.02 Billion JPY | 125.417% |
| SanBio Company Limited | -2.64 Billion JPY | 109.846% |
| Healios K.K. | -3.82 Billion JPY | 106.81% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 122.287% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 117.476% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 118.213% |
| StemRIM | -2.02 Billion JPY | 112.875% |
| CellSource Co., Ltd. | 923.14 Million JPY | 71.8% |
| FunPep Company Limited | -933.41 Million JPY | 127.89% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 130.478% |
| Stella Pharma Corporation | -763.74 Million JPY | 134.086% |
| TMS Co., Ltd. | -960.04 Million JPY | 127.117% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 123.038% |
| Cuorips Inc. | -632.18 Million JPY | 141.18% |
| Takara Bio Inc. | 1.48 Billion JPY | 82.41% |
| ReproCELL Incorporated | -31.41 Million JPY | 928.681% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -886.921% |
| StemCell Institute Inc. | 310.98 Million JPY | 16.287% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -81.834% |
| CellSeed Inc. | -846.53 Million JPY | 130.752% |